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Background. Current advances in genetic technology continue to expand the list of medical conditions associated with autism.
Clinicians have to identify speciﬁc autistic-related syndromes, and to provide tailored counseling. The aim of this study is to
elucidate recent advances in autism research that oﬀer important clues into pathogenetic mechanisms of syndromic autism
and relevant implications for clinical practice. Data Sources. The PubMed database was searched with the keywords “autism”
and “chromosomal abnormalities,” “metabolic diseases,” “susceptibility loci.” Results. Deﬁned mutations, genetic syndromes,
and metabolic diseases account for up to 20% of autistic patients. Metabolic and mitochondrial defects may have toxic eﬀects
on the brain cells, causing neuronal loss and altered modulation of neurotransmission systems. Alterations of the neocortical
excitatory/inhibitory balance and perturbations of interneurons’ development represent the most probable pathogenetic
mechanisms underlying the autistic phenotype in Fragile X-Syndrome and Tuberous Sclerosis Complex. Chromosomal
abnormalities and potential candidate genes are strongly implicated in the disruption of neural connections, brain growth,
and synaptic/dendritic morphology. Conclusion. Metabolic testing may be appropriate if speciﬁc symptoms are present. High-
resolution chromosome analysis may be recommended if a speciﬁc diagnosis is suspected because of obvious dysmorphisms.
Identifying cryptic chromosomal abnormalities by whole genome microarray analysis can increase the understanding of the
neurobiological pathways to autism.
Copyright © 2009 A. Benvenuto et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Autism and related autism spectrum disorders (ASDs) are
heterogeneous neurodevelopmental disorders behaviorally
deﬁned by signiﬁcant deﬁcits in social interaction and com-
munication and by the presence of restricted interests and
repetitive behaviors [1]. Autism Disorder (AD) comorbidy
withseizuresandmentalretardationoccursinupto30%and
in 80% of autistic patients, respectively [2]. Its pathogenetic
substrates are still largely unknown. Despite strong familial
components,clinicalcomplexity hasposed amajorchallenge
to our understanding of autism pathogenesis. Genetically,
the picture is complicated by signiﬁcant interindividual
heterogeneity, numerous contributing loci, and multiple
genes and gene-environment interactions [3]. Several lines
of evidences strongly support a prenatal onset for devel-
opmental abnormalities later leading to autism [4]. Autism
in its very broad spectrum of severity is known to have
many diﬀerent etiologies. In the last few years, signiﬁcant
progresses have been made in comprehending the causes
of autism, and their multiple impacts on the developing
brain [5]. The primary goals of treatment are optimizing the
qualityoflifeandminimizingtheimpairmentduetothecore
symptoms of autism [6].
In this article we discuss current understanding of the
pathogenesisofsyndromicautismandthemultiplepathways
responsible for the ASD phenotype.
2.Metabolic Diseases
Several inborn errors of metabolism, including phenylke-
tonuria, biotinidase deﬁciency, disorders of cerebrospinal
ﬂuid (CSF) neurotransmitters such as deﬁciencies of folic
acid, Smith-Lemli-Opitz syndrome (SLOS), creatine deﬁ-
ciencysyndromes, metabolic purine disorders, haveanautis-
tic phenotype [7]. A better understanding of some of them
has implications both for discovery of the pathophysiologic
underpinnings of the disorder and for the development of
eﬀective interventions.2 International Journal of Pediatrics
In untreated children aﬀected by phenylketonuria, the
high levels of phenylalanine may have toxic eﬀects on
the brain cells, causing reduction of myelin, neuronal
loss, and decreased levels of interneuronal connections [8].
Hyperphenylalaninemia also competes with the absorbition
of other amino acids and consequently lower tyrosine and
tryptophan concentrations can result in a low production of
dopamine and serotonin in the prefrontal cortex [9].
Insomeofthemostseveremetabolicdiseases,likeadeny-
losuccinase deﬁciency or creatine deﬁciency syndromes,
neurological and behavioral symptoms are probably not
caused by deﬁciency of metabolites, but are more likely
due to the toxic eﬀects of the accumulating substances on
the brain [8]. A direct role in modulation of dopaminergic
and serotoninergic neurotransmission systems and axonal
guidancehasbeenhypothesizedfortheadenosinedeaminase
deﬁciency as pathologic mechanisms for the development
of altered pathways involved in autistic symptoms [10]. The
role of mitochondrial disorders has been revitalized by the
association between autism and variants of the SLC25A12
gene, which encodes the predominant isoform of the mito-
chondrial aspartate (asp)/glutamate (glu) carrier (AGC) in
brain [11]. Altered Ca2+ homeostasis is responsible for
boosting AGC activity, mitochondrial metabolism, and, to a
more variable degree, oxidative stress in autistic brains [12].
Basedonourclinicalexperience,routinemetabolicscreening
studiesshouldbeusedonacaseby-casebasis,inthepresence
of the autistic regression, or suggestive clinical ﬁndings, such
as lethargy, cyclic vomiting, early onset seizures, dysmor-
phic features, mental retardation with neurologic deﬁcits,
unexplained immune deﬁciency or unexplained hemolytic
anemia, hyper- or hypotonia, self-mutilation, and muscle
weakness[13].Table 1 summarizesthemainclinicalfeatures,
diagnostic test and therapeutic options of the metabolic
diseases most frequently associated with ASD.
3.EpilepsyandRegressiveAutism
The relationship among epilepsy, autism, and regression is
a poorly understood and controversial subject. There are
several epilepsy syndromes in which regression of language,
cognition, and behavior may lead to clinical manifestations
that overlap with the behavioral syndrome of autism, such
as infantile spasms, slow spike-wave discharges during sleep,
and focal centrotemporal spikes. An epileptic disorder must
be considered in all children with a low functioning ASD,
especially when a history of regression and electroen-
cephalogram (EEG) epileptic abnormalities is present [14].
Severe epileptiform abnormalities may permanently alter the
critical synaptogenesis by strengthening synaptic contacts
that should have been naturally pruned [15]. Cognitive
functionsdeclineinthosepatientswhohaveearly-onsetEEG
abnormalities and a prolonged active phase of continuous
spike-and-wave discharges during sleep [16]. In children
withautisticregression,thereisnoevidencethattreatmentof
the seizures or of the interictal epileptiform activity makes a
diﬀerenceinregardtotheoutcomeofthelanguageandsocial
deﬁcits. Because the relationship between autism, epilepsy,
and regression is complex, the clinician’s index of suspicion
for epilepsy should be high, and treatment of the epilepsy
should be pursued when necessary.
Although the pathogenetic link between autism and
epilepsy is poorly understood, the existence of altered Ca2+
signaling in ASD and the bioelectrical instability resulting
from mutations of the L-type voltage-gated Ca2+ channels
associated to autism may account for the high prevalence
of seizures and/or EEG abnormalities present among autistic
individuals [17].
4.GeneticDiseasesAssociatedwithAutism
Single gene defects and chromosomal abnormalities may
account for approximately up to 10% [18] of individuals
with autism, and the fraction is likely to be higher when
microarray comparative genome hybridization is used [19].
Table 2 summarizes the most frequent genetic syndromes
and cytogenetic abnormalities associated with autism.
4.1. Fragile X Syndrome. Abnormalities in long-term synap-
tic plasticity of excitatory synapses and in baseline synaptic
connectivity may be the underlying neurological substrate
of autism associated with FXS [20, 21]. Alterations in the
neocortical excitatory/inhibitory balance as well as abnormal
neural synchronization have been also reported in mouse
model of FXS [22], resulting in hyperexcitability of neocor-
tical circuits. An immature dendritic morphology may also
increasesusceptibilitytoepilepsyandanxietyinFXSpatients
[23].
4.2. Tuberous Sclerosis Complex. Tuberous sclerosis complex
(TSC) is an inherited disorder resulting from mutations in
one of two genes, TSC1 (Hamartin) and TSC2 (Tuberin),
characterized by benign hamartomatous tumors that involve
multiple organ systems. It is commonly associated with
neuropsychiatriccomplicationslikeepilepsy,mentalretarda-
tion, autism, and other behavioral problems. Seizures can be
present in the ﬁrst year of life and up to one third of children
develop infantile spasms. Neurobehavioral phenotypes in
TSC may arise from perturbations of interneurons devel-
opment, which can selectively impact frontal and parietal
areas [24]. TSC2 gene localized on 16p13.3 locus encodes
for tuberin, a protein highly expressed in frontal regions
[25]. Furthermore, several studies have described the TSC
1 locus 9q34 as an important region of vulnerability for the
developmentalofautism.AlossofasingleTSC1genecopyin
mice is suﬃcient to perturb cytoskeletal dynamics and den-
dritic spine structure, highlighting generalized neurotrophic
roles for these genes, in addition to cell growth regulation.
Circuitry alterations are the possible biological substrate of
autism associated with TSC.
5. Chromosomal Abnormalities
A wide number of cytogenetic abnormalities have been
described [26], particularly in the low functioning autistic
population with dysmorphic features [27].International Journal of Pediatrics 3
Table 1: Diagnosis and potential therapeutic approaches in some metabolic diseases associated with autism.
Metabolic diseases Potential patogenetic
mechanisms Clinical features Diagnosis Therapetic
options
Refs
Phenylketonuria
Low production of
dopamine and
serotonin. Toxic
eﬀects on the brain
cells. Reduction of
myelin.
Neonatal onset Autism, seizures,
severe mental retardation,
hyperactivity, EEG abnormalities
and seizures, microcephaly,
albinism (excessively fair hair and
skin) or a tendency to
hypopigmentation and eczema,
“musty or mousy” odor of skin,
hair, sweat, and urine.
Quantitative plasma
amino acids analysis.
Dosage of
phenylpyruvic acid in
urine.
Restricted diet +
aminoacids
administration.
[28, 29]
Adenylosuccinase
deﬁcit
Toxic eﬀects of the
accumulating succinyl
purines on the brain.
Onset in the ﬁrst year. Autistic
phenotype, profound psychomotor
retardation, epilepsy, hypotonia,
peripheral hypertonia, failure to
thrive. No dismorphic features.
Succinyl
aminoimidazole,
carboxamide riboside
and succinyl
adenosine in urine
and cerebrospinal
ﬂuid.
Therapy with
D-ribose. [7, 30]
Smith-Lemli-Opitz
syndrome
Neurosteroid
deﬁciency. Alteration
of neuroendocrine
functions and
disruption of the
growth and
development of many
body systems.
Onset in infancy. Autism, mental
retardation, sensory hyperreactivity,
irritability, language impairment,
sleep cycle disturbance,
self-injurious behavior,
microchepaly, hypotonia,
syndactyly, hypogenitalism,
malformations of the brain, lung,
heart, and gastrointestinal tract.
Abnormal sterol
pattern (low plasma
and tissue cholesterol
concentrations, and
increased plasma and
tissue
7-dehydrocholesterol
reductase and its
metabolite).
Cholesterol
replacement
therapy.
[31, 32]
Creatine deﬁciency
syndromes
Neurotoxic eﬀect of
guanidinoacetate or
other guanidine
compounds.
Autistic phenotype, mental
retardation, speech delay, epilepsy,
extrapyramidal symptoms,
progressive encephalopathy with
muscular hypotonia, dyskinetic
movements, developmental
arrest/regression.
Blood and urinary
concentration on
creatine and
guanidinoacetate,
Brain magnetic
resonance
spectroscopy.
Oral creatine
supplementa-
tion. Restriction
of arginine and
substitution of
ornithine.
[33]
Genes
Maternal
factors
Toxins and
infections
Ossidative
stress
Brain development
Intra-
uterine
0–40
weeks
Postnatal
First years
Brain
maturation
Second-
third year
Neurobiological
trajectories
Neuronal
organization
Sinaptic/dendritic
modeling
Cortical networks
development
Brian growth
Alterated
developmental
trajectories
Social
interaction
Language and
communication
Repetitive
behaviors
Figure 1:Geneticandepigeneticfactorsinvolvedinthepathogenesisofautism.Interactionsbetweenmultiplegenesandenvironmentalfactors,
such as intrauterine infections, alcohol/toxins exposure, and obstetrical suboptimality, can inﬂuence intrauterine and early postnatal brain
development and disrupt crucial neurobiological pathways, from neuronal migration and cortical organization to synaptic and dendritic
conformation, resulting in alterations of neurobehavioral trajectories that are involved in the pathogenesis of ASD.
5.1. Chromosome 15. Chromosomal rearrangements in
15q11-15q13 region might be the most frequent cytogenetic
abnormality in ASD [34], accounting for 1–2% of patients.
A chromosome 15 phenotype II , characterized by ataxia,
languagedelay,epilepsy,mentalretardation,repetitivemove-
ment disorders, and facial dysmorphic features, has been
described in individuals with chromosome 15 duplications
[35]. Within the 15q11–15q13 locus, gamma-aminobutyric
acid A receptor beta 3 (GABRB3), an inhibitory neurotrans-
mitter receptor, are currently thought to be central likely to
play a signiﬁcant role in the development of ASD, due to its
role in the neuronal inhibition and its expression in early4 International Journal of Pediatrics
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Figure 2: Potential pathogenetic mechanisms of syndromic autism. Several medical conditions associated with syndromic autism appear
to inﬂuence and potentially disrupt neurodevelopmental processes, including brain growth, cortical connectivity, and neurotransmitters
pathways. These neurobiological alterations likely aﬀect the developmental trajectory of social behavior and communication during early
stages of childhood and determine the diﬀerent clinical phenotypes of ASD.
development [36]. This ﬁnding is particularly interesting in
light of the high incidence of seizures and EEG abnormalities
in autistic patients.
5.2. Chromosome 7. Two of the loci most commonly asso-
ciated with ASD by genetic linkage studies [37, 38] (7q22
and 7q31 regions) contain several genes implicated in the
pathogenesis of autism. The RELN gene, found within
the 7q22 region, has a pivotal role in neuronal migration
and prenatal development of neural connections, [39, 40]
and is potently inhibited by toxic substances, such as
organophosphates [41].
Increased risk for autism can be also linked to a
functional polymorphism in the MET gene, found within
the 7q31 locus [42], which plays a role into development
of the cerebral cortex and cerebellum. The Williams-Beuren
syndrome (WBS) region (7q11.23) also contains several
genes associated with impairment in language and social
interaction [43–45], suggesting the existence of a speciﬁc
subgroup of autistic patients, characterized by dysmorphic
features, mental retardation, language delay, congenital heart
disease, and hypersensitivity to sound.
5.3. Chromosome 16. An association between a larger
microdeletion on 16p11.2 and a syndrome that included
developmental delay and distinct facial appearance (hyper-
telorism, a broad nasal bridge and a broad nasal tip with
a prominent columella, a short philtrum, long ears, a large
mouth) has been described [46–48]. The chromosomal
region 16p11.2 also encompasses the PRKCB1 locus, an
interesting gene previously found associated with autism
[49], and expressed in the CNS, the immune system, the
digestive tract, and the kidney. A recent study has described
an association between PRKCB1 and an enhanced urinary
peptide excretion rate [50].
5.4. Chromosome 2. Deletions involving 2q37 have been
observed in more than 70 individuals with autism, mental
retardation, and dysmorphic features (prominent forehead,
depressed nasal bridge, dysmorphic ears and nose, short
stature, and short hands and feet) [51, 52]. Three diﬀerent
breakpoints of 2q37 (2q37.1, 2q37.2, 2q37.3) have been
analyzed to clarify the genotype-phenotype relationships
associated with diﬀerent terminal deletions [53], and several
candidate genes for autism have been identiﬁed in 2q37.3
band [54]. Furthermore, a correlation between autism and
a de novo cryptic deletion of chromosome 2p25.2 has been
described [55]. The interaction between potential candidate
genes that are expressed on these loci may explain the
phenotypical heterogeneity and the spectrum of neuropsy-
chological deﬁcits associated with 2q37 and 2p25.2 deletion
syndromes.
Other regions implicated in the ASDs with possible
candidate genes are summarizes in Table 3.
6. Pathogenetic Pathways
Several molecular pathways potentially involved in the dis-
ruptionofneurodevelopmentaltrajectoriesduringintrauter-
ine or postnatal brain development may be associatedInternational Journal of Pediatrics 5
Table 2: Genetic syndromes associated with autism.
Syndrome
Gene(s)
associated
with the
syndrome
Proportion of
patients with an
ASD that have the
syndrome
Proportion of
patients with the
syndrome that
have an ASD
Clinical signs Refs
Fragile-X
syndrome FMR1 2–5% 20–40%
Mental retardation, long face with prominent
ears, macroorchidism, social anxiety, sensory
hypersensitivity, stereotypies, poor motor
coordination, delayed speech development.
[56, 57]
Tuberous
sclerosis
TSC1,
TSC2 3–4% 43–86%
Epilepsy, mental retardation, speciﬁc learning
disabilities, ADHD disorder, autistic spectrum
disorders.
[58, 59]
15q duplication
Angelman/Prader
Will syndrome
UBE3A
GABAr
cluster
1–2% >40%
Ataxia, language delay, epilepsy, mental
retardation, repetitive movements,
obsessive-compulsive symptoms.
[60]
16p11 deletion PCKB1 1% High
Developmental delay, distinct facial appearance,
autism. [46, 61]
22q deletion SHANK3 1% High
Speech and language disability, social
impairment. [62, 63]
2q37 deletion KIF1A,
GBX2 Unknown 50%
D e v e l o p m e n t a ld e l a y ,m e n t a lr e t a r d a t i o n ,
hypotonia, hyperactivity, autistic traits,
dysmorphic features (cleft palate, temporal bone
abnormalities, hypoplastic lungs).
[64]
Joubert syndrome AHI1 Unknown 40%
Partial/complete agenesis of the cerebellar
vermis, ataxia, abnormalities of ocular
movements, cognitive, and behavioral
dysfunction.
[65]
Timothy
syndrome CACNA1C Unknown 60–70%
Cardiac arrhythmia, long QT syndrome, mental
retardation, and ASD. [66]
Cortical
dysplasia-focal
epilepsy
syndrome
CNTNAP2 Rare 70% Seizures and language regression. [67, 68]
with abnormal developmental processes, from neuronal
migration and cortical organization to synaptic and den-
dritic conformation [69]. Furthermore, environmental fac-
tors, including maternal/intrauterine infections, exposure
to toxins, and ossidative stress, may modify the under-
lying genetic substrate and leading to abnormalities in
neuronal organization and cortical network development
[70]. Figure 1 summarizes both genetic background and
epigenetic factors involved in the pathogenesis of ASD,
and explains how their multifactorial inﬂuence may be
necessary for full expression of the autistic phenotype.
Deﬁned medical syndromes, chromosomal abnormalities
and de novo copy number variations (CNVs) may account
for10% ofASDcases[71].Figure 2illustratesmanydiﬀerent
types of potential pathogenetic mechanisms responsible for
the ASD phenotype in the most common medical conditions
associated with autism. Widespread genetic testing would
be expensive, time-consuming, and generally inappropriate
due to the etiological complexity, while the appropriate use
of genetic testing in subgroups of autistic patients showing
particularclinicalfeaturesisrelevanttogoodclinicalpractice
and may allow the identiﬁcations of new susceptibility
variants. The advent of ﬂuorescent in situ hybridization
(FISH) techniques has expanded the list of chromosomal hot
spots in autism. Individual FISH studies may be indicated in
theconﬁrmationofaclinicallysuspectedcondition[72],and
in the evaluation of low functioning patients with an IQ <50
[73]. When dysmorphic features are present, it is reasonable
to suspect chromosomal rearrangements even if the kary-
otype appears normal, and oligo-array-based CGH analysis
is highly advisable in these cases [74]. Whole genome-
scanning by array-based technology has detected copy-
number variations (CNVs), which are copy-number changes
involving a DNA fragment, and represent submicroscopic
deletions or duplications that are undetectable at the routine
cytogenetic analysis [75–78]. In conclusion, as etiologies of
ASD are progressively discovered, the number of individuals
with idiopathic autism will progressively shrink. The role of
the neuropediatrician will be to understand the neurological
basisofautism,andtoidentifymorehomogenoussubgroups
with speciﬁc biologic markers. Because autism represents
an extremely heterogeneous group of disorders, a better6 International Journal of Pediatrics
Table 3: Candidate genes associated with autism.
Genes Chromosomes Proteins Proteins’ functions Neurobiological
abnormalities Clinical phenotypes Refs
NGL3
NGL4
Xq13.1
Xp22.3
Neuroligin
3/4.
Synaptic
transmission,
diﬀerentiation of
synaptic contacts.
Synaptic or dendritic
changes.
Autism with motor tics, Mild to
severe autism, PDD-NOS,
“regression” at disease onset, with a
loss of initially-acquired social and
verbal milestones, no dysmorphic
features.
[79, 80]
SHANK3 22q13
Shank
scaﬀolding
proteins.
Master organizer of
postsynaptic
glutamatergic density.
Synaptic or dendritic
changes.
Multiple developmental delays,
dysmorphic features, autism with
severe language/social deﬁcits.
[81, 82]
MET/HGF 7q31
MET recep-
tortyrosine
kinase/
hepatocyte
growth
factor.
Regulation of
dendritic morphology
and promoting
neurite outgrowth.
Abnormalities in
development of the
cerebral cortex and
cerebellum.
Autism, increased anxiety, seizures,
immune, and gastrointestinal
problems.
[83]
MECP2 Xq28
Methyl-CpG-
binding
protein 2.
Synapse maintenance
and remodeling.
Synaptic or dendritic
changes.
Rett syndrome with regression,
mental retardation, microcephaly,
stereotyped behaviors, epilepsy and
breathing problems; verbal Rett
variants.
[84]
HOXA1 7p15.3 Homeobox
protein.
Regulation of brain
growth.
Abnormalities of
numbers of neurons
or glia in the brain.
Mental retardation, autism and
distinct clinical features (horizontal
gaze abnormalities, focal weakness,
hypoventilation, vascular
malformations).
[85]
PTEN 10q23
phosphatase
and tensin
homologue.
Regulation of cells
proliferation/
diﬀerentiation.
Abnormalities in
brain growth.
Macrocephaly, macrosomia, autism
and developmental delay, increased
risk of developing a variety of
PTEN-related cancers in adulthood.
[86, 87]
understanding of underlying biological processes will lead to
more targeted intervention approaches that can be designed
for speciﬁc subtypes of autism.
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